Artificial Intelligence Clinical Trial Protocol Feasibility Tool Market Report 2026

The artificial intelligence clinical trial protocol feasibility tool market size has grown exponentially in recent years. It will grow from $0.83 billion in 2025 to $1.06 billion in 2026 at a compound annual growth rate (CAGR) of 27.3%. The growth in the historic period can be attributed to increasing protocol complexity in clinical trials, rising trial failure rates, growing reliance on data-driven feasibility analysis, expansion of global clinical research activity, early adoption of ai-based planning tools.

The artificial intelligence clinical trial protocol feasibility tool market size is expected to see exponential growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 27%. The growth in the forecast period can be attributed to increasing demand for faster trial approvals, rising adoption of decentralized trial designs, expansion of ai-enabled protocol optimization platforms, growing focus on trial cost reduction, increasing emphasis on predictive feasibility modeling. Major trends in the forecast period include increasing use of ai for protocol risk assessment, rising adoption of predictive recruitment modeling, growing integration of historical trial data, expansion of cloud-based feasibility tools, enhanced focus on trial design optimization.

The growing focus on precision medicine is expected to drive the growth of the artificial intelligence clinical trial protocol feasibility tool market in the coming years. Precision medicine is a healthcare approach that tailors treatments based on a patient’s genetics, environment, and lifestyle to provide more accurate and effective therapies. This focus is increasing due to advancements in genomic sequencing and biomarker identification, which enable precise detection and targeted treatments. AI clinical trial protocol feasibility tools support precision medicine by facilitating data-driven trial design, making it possible to tailor therapies to specific patient populations. They help reduce trial inefficiencies by predicting patient recruitment, timelines, and risks, thereby improving clinical research accuracy and outcomes. For example, in March 2024, Novotech, an Australia-based biotechnology company, reported that in 2023, 43% of the 217 FDA-approved oncology therapies were precision oncology treatments, with 78 incorporating DNA or NGS-detectable biomarkers. The rising emphasis on precision medicine is therefore fueling the growth of the AI clinical trial protocol feasibility tool market.

Key players in the AI clinical trial protocol feasibility tool market are developing innovative solutions such as predictive analytics-based trial planning software to improve protocol accuracy and reduce trial delays. Predictive analytics-based trial planning software uses historical and real-time clinical trial data to forecast timelines, identify risks, and optimize study design for more efficient and cost-effective trials. For instance, in June 2024, Lokavant Inc., a US-based clinical intelligence company, launched Spectrum, the first AI clinical trial feasibility solution designed to optimize trials from strategic planning through mid-study re-forecasting. The platform integrates predictive analytics-based trial planning to enable continuous, real-time feasibility analysis, timeline and cost prediction, and financial forecasting without manual intervention. Spectrum provides dynamic, real-time (re)forecasting by incorporating live trial data, allowing study teams to monitor progress, evaluate alternative scenarios, and optimize enrollment outcomes. The solution delivers highly accurate predictions for timelines, costs, and operational risks, supporting faster, data-driven decision-making throughout the clinical trial lifecycle.

In March 2025, Tempus AI Inc., a US-based health technology company, acquired Deep 6 AI for an undisclosed amount. Through this acquisition, Tempus AI aims to accelerate patient recruitment, expand access to real-world data, and advance precision medicine by enhancing AI-driven clinical trial matching. Deep 6 AI Inc. is a US-based provider of advanced AI clinical trial protocol feasibility tools.

Major companies operating in the artificial intelligence clinical trial protocol feasibility tool market are IQVIA Holdings Inc., SAS Institute Inc., Veeva Systems Inc., Tempus AI Inc., Cytel Inc., ArisGlobal LLC., Saama Technologies Inc., Norstella, ConcertAI, Komodo Health Inc., H1 Inc., TriNetX Inc., ObjectiveHealth LLC, Lokavant Inc., Inato Inc., Clinerion Ltd., Faro Health Inc., Lantern Pharma Inc., Ryght AI, BEKHealth Corporation.

North America was the largest region in the artificial intelligence clinical trial protocol feasibility tool market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence clinical trial protocol feasibility tool market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence clinical trial protocol feasibility tool market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the AI clinical trial protocol feasibility tool market by increasing costs related to imported data infrastructure hardware, advanced analytics platforms, and specialized software components used in protocol modeling solutions. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on cross-border technology vendors, while Asia-Pacific experiences pricing pressure on cloud-based analytics services. These tariffs are increasing operational expenses and slowing software upgrades. However, they are also encouraging regional software development, localized data infrastructure investments, and greater adoption of domestically developed AI trial planning tools.

The artificial intelligence clinical trial protocol feasibility tool market research report is one of a series of new reports that provides artificial intelligence clinical trial protocol feasibility tool market statistics, including artificial intelligence clinical trial protocol feasibility tool industry global market size, regional shares, competitors with a artificial intelligence clinical trial protocol feasibility tool market share, detailed artificial intelligence clinical trial protocol feasibility tool market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence clinical trial protocol feasibility tool industry. This artificial intelligence clinical trial protocol feasibility tool market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An artificial intelligence clinical trial protocol feasibility tool is a software solution that leverages AI algorithms to analyze historical clinical data, patient populations, and trial design parameters to evaluate the feasibility of a proposed clinical trial. Its main purpose is to predict patient recruitment potential, identify protocol risks, and optimize trial design, helping to reduce delays and improve trial success rates.

The key components of the AI clinical trial protocol feasibility tool are software and services. The software is a digital platform that uses AI to assess clinical trial protocols, forecast patient recruitment, identify risks, and optimize trial design for faster, more efficient studies. It can be deployed through cloud-based or on-premises modes. The tool has multiple applications, including protocol design, site selection, patient recruitment, risk assessment, and more, serving a variety of end users such as pharmaceutical and biotechnology companies, contract research organizations, academic and research institutes, and other relevant organizations.

The artificial intelligence clinical trial protocol feasibility tool market includes revenues earned by entities through patient recruitment analysis, site selection optimization, protocol design feasibility, risk assessment and mitigation, and data integration and analytics services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.